Biological profiling of novel tricyclic inhibitors of bacterial DNA gyrase and topoisomerase IV

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 7, 2016, Pages 1905-1913

  Savage, Victoria J ^a   Charrier, Cédric ^a   Salisbury, Anne Marie ^a   Moyo, Emmanuel ^a   Forward, Henry ^a   Chaffer Malam, Nathan ^a   Metzger, Richard ^a   Huxley, Anthony ^a   Kirk, Ralph ^a   Uosis Martin, Mario ^a   Noonan, Gary ^a   Mohmed, Sarfraz ^a   Best, Stuart A ^a   Ratcliffe, Andrew J ^a   Stokes, Neil R ^a  

^a REDX PHARMA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; GYRASE INHIBITOR; LEVOFLOXACIN; LINEZOLID; REDX 04139; REDX 05604; REDX 05931; RIFAMPICIN; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; HYDROCARBON;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; BROTH DILUTION; COMPARATIVE STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; ENZYME ASSAY; ENZYME INHIBITION; GEL ELECTROPHORESIS; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMA PROTEIN BINDING; SEPTICEMIA; STAPHYLOCOCCUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOAVAILABILITY; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECTS; HEP-G2 CELL LINE; HUMAN; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STREPTOCOCCUS; SURVIVAL ANALYSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL AVAILABILITY; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DNA GYRASE; DNA TOPOISOMERASE IV; HEP G2 CELLS; HUMANS; HYDROCARBONS, CYCLIC; MALE; MICE; MICROBIAL SENSITIVITY TESTS; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STREPTOCOCCUS; SURVIVAL ANALYSIS;

EID: 84979022100     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw061     Document Type: Article

References (32)

1. Sakoulas G, Moellering RC. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008; 46 Suppl 5: S360-7
2. WHO. Antimicrobial Resistance: Global Report on Surveillance. 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/
3. Gillespie SH, Singh K. XDR-TB, what is it; how is it treated; and why is therapeutic failure so high? Recent Pat Antiinfect Drug Discov 2011; 6: 77-83
4. O'Neill J. Securing New Drugs for Future Generations: The Pipeline of Antibiotics. 2015. http://amr-review.org/sites/default/files/SECURING%20NEW%20DRUGS%20FOR%20FUTURE%20GENERATIONS%20FINAL%20WEB_0.pdf
5. O'Neill J. Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. 2014. http://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf
6. Ratcliffe A, Huxley A, Lyth D et al. Antibacterial Compounds. PCT/GB2015/051107. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2015155549
7. Schoeffler AJ, Berger JM. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys 2008; 41: 41-101
8. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-40
9. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem 2001; 70: 369-413
10. Mitscher LA. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev 2005; 105: 559-92
11. Redgrave LS, Sutton SB, Webber MA et al. Fluoroquinolone resistance: mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol 2014; 22: 438-45
12. Maxwell A. The interaction between coumarin drugs and DNA gyrase. Mol Microbiol 1993; 9: 681-6
13. Alt S, Mitchenall LA, Maxwell A et al. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics. J Antimicrob Chemother 2011; 66: 2061-9
14. Anderle C, Stieger M, Burrell M et al. Biological activities of novel gyrase inhibitors of the aminocoumarin class. Antimicrob Agents Chemother 2008; 52: 1982-90
15. BSAC. Resistance Surveillance Project. 2013. http://www.bsacsurv.org/
16. Huband MD, Cohen MA, Zurack M et al. In vitro and in vivo activities of PD 0305970 and PD 0326448, new bacterial gyrase/topoisomerase inhibitors with potent antibacterial activities versus multidrug-resistant grampositive and fastidious organism groups. Antimicrob Agents Chemother 2007; 51: 1191-201
17. Unemo M, Ringlander J, Wiggins C et al. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014. Antimicrob Agents Chemother 2015; 59: 5220-5
18. Biedenbach DJ, Huband MD, Hackel Met al. In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens. Antimicrob Agents Chemother 2015; 59: 6053-63
19. Pucci MJ, Podos SD, Thanassi JA et al. In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens. Antimicrob Agents Chemother 2011; 55: 2860-71
20. Flamm RK, Vojtko C, Chu DTet al. In vitro evaluation of ABT-719, a novel DNA gyrase inhibitor. Antimicrob Agents Chemother 1995; 39: 964-70
21. Singh SB. Confronting the challenges of discovery of novel antibacterial agents. Bioorg Med Chem Lett 2014; 24: 3683-9
22. So W, Crandon JL, Nicolau DP. Pharmacodynamic profile of GSK2140944 against methicillin-resistant Staphylococcus aureus in a murine lung infection model. Antimicrob Agents Chemother 2015; 59: 4956-61
23. Bax BD, Chan PF, Eggleston DS et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010; 466: 935-40
24. Savage V, Charrier C, Stokes N. Antibiotic-resistant bacteria and their uses. PCT/GB2015/052308. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016024098&recNum=1&office=&queryString=FP%3A%28052308%29prevFilter=&sortOption=Pub+Date+Desc&maxRec=68
25. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012
26. Drago L, De Vecchi E, Mombelli B et al. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother 2001; 48: 37-45
27. Hyatt JM, Nix DE, Schentag JJ. Pharmacokinetic and pharmacodynamic activities of ciprofloxacin against strains of Streptococcus pneumoniae, Staphylococcus aureus, and Pseudomonas aeruginosa for which MICs are similar. Antimicrob Agents Chemother 1994; 38: 2730-7
28. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997; 24 Suppl 1: S67-73
29. Takei M, Fukuda H, Kishii R et al. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob Agents Chemother 2001; 45: 3544-7
30. Ferrero L, Cameron B, Crouzet J. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 1554-8
31. Liu XG, Li RC. Effects of repeated rifabutin administration on the pharmacokinetics of intravenous and oral ciprofloxacin in mice. J Chemother 2001; 13: 563-8
32. Estes KS, Derendorf H. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecycline, and daptomycin. Eur J Med Res 2010; 15: 533-43